<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01021761</url>
  </required_header>
  <id_info>
    <org_study_id>2009 0199</org_study_id>
    <nct_id>NCT01021761</nct_id>
  </id_info>
  <brief_title>A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification</brief_title>
  <official_title>A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail, Xibrom and Nevanac in Patients Undergoing Phacoemulsification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frank A. Bucci, Jr., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bucci Laser Vision Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 126 subjects scheduled to undergo cataract surgery by phacoemulsification, will
      be randomized in an even allocation (1:1:1) to either Acuvail, Xibrom or Nevanac. Subjects
      will be instructed to begin dosing the study medication in the operative eye the day before
      surgery and continue dosing on the day of surgery. Beginning one hour before surgery 1 drop
      of study medication will be instilled by operating room staff approximately every 15 minutes
      for a total of 3 doses. At the designated time a paracentesis will be performed at the start
      of the cataract procedure and at least 0.15cc of aqueous humor will be collected. The sample
      will be immediately stored on dry ice and shipped to a laboratory for analysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aqueous PGE2 Inhibition</measure>
    <time_frame>Day 4 of treatment</time_frame>
    <description>A spectroscopic quantification of PGE2 was performed on the aqueous humor samples collected with the results measured in pg/ml. PGE2 levels below 50 pg/ml were considered below the level of detection.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>Xibrom</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xibrom to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nevanac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nevanac to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acuvail</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acuvail to be given preoperatively. One drop 2 times (BID), 1 day pre op and day of surgery 3 doses prior to surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine</intervention_name>
    <description>ketorolac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
    <arm_group_label>Acuvail</arm_group_label>
    <other_name>Acuvail</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromfenac</intervention_name>
    <description>Drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
    <arm_group_label>Xibrom</arm_group_label>
    <other_name>Xibrom</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nepafenac</intervention_name>
    <description>drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
    <arm_group_label>Nevanac</arm_group_label>
    <other_name>Nevanac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be 18 years of age or older

          -  Scheduled for cataract surgery by phacoemulsification

          -  Subjects must be willing to comply with all study requirements and be willing to give
             informed consent

        Exclusion Criteria:

          -  Any subject that has a history of uveitis or active iritis

          -  Subject can have o previous eye surgery with the exception of refractive surgery but
             not within 6 month

          -  No ocular use of prostaglandins within 2 weeks of surgery

          -  Use of oral, injectable or topical ophthalmic steroids, NSAIDs of immunosuppressants
             within 14 days prior to surgery

          -  Contraindications to nonsteroidal anti-inflammatory drugs (NSAIDs)

          -  Active ocular infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank A Bucci, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bucci Laser Vision</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2009</study_first_submitted>
  <study_first_submitted_qc>November 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2009</study_first_posted>
  <results_first_submitted>May 25, 2011</results_first_submitted>
  <results_first_submitted_qc>July 28, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2011</results_first_posted>
  <last_update_submitted>August 26, 2011</last_update_submitted>
  <last_update_submitted_qc>August 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bucci Laser Vision Institute</investigator_affiliation>
    <investigator_full_name>Frank A. Bucci, Jr., M.D.</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Xibrom</title>
          <description>Xibrom to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
        </group>
        <group group_id="P2">
          <title>Nevanac</title>
          <description>Nevanac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
        </group>
        <group group_id="P3">
          <title>Acuvail</title>
          <description>Acuvail to be given preoperatively. One drop BID, 1 day pre op and day of surgery 3 doses prior to surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Xibrom</title>
          <description>Xibrom to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
        </group>
        <group group_id="B2">
          <title>Nevanac</title>
          <description>Nevanac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
        </group>
        <group group_id="B3">
          <title>Acuvail</title>
          <description>Acuvail to be given preoperatively. One drop BID, 1 day pre op and day of surgery 3 doses prior to surgery.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="42"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="31"/>
                    <measurement group_id="B2" value="74" spread="29"/>
                    <measurement group_id="B3" value="75" spread="30"/>
                    <measurement group_id="B4" value="74" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Aqueous PGE2 Inhibition</title>
        <description>A spectroscopic quantification of PGE2 was performed on the aqueous humor samples collected with the results measured in pg/ml. PGE2 levels below 50 pg/ml were considered below the level of detection.</description>
        <time_frame>Day 4 of treatment</time_frame>
        <population>Protocol specified 126 subjects to be enrolled and analysis was performed per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Xibrom</title>
            <description>Xibrom to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
          </group>
          <group group_id="O2">
            <title>Nevanac</title>
            <description>Nevanac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
          </group>
          <group group_id="O3">
            <title>Acuvail</title>
            <description>Acuvail to be given preoperatively. One drop BID, 1 day pre op and day of surgery 3 doses prior to surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Aqueous PGE2 Inhibition</title>
          <description>A spectroscopic quantification of PGE2 was performed on the aqueous humor samples collected with the results measured in pg/ml. PGE2 levels below 50 pg/ml were considered below the level of detection.</description>
          <population>Protocol specified 126 subjects to be enrolled and analysis was performed per protocol.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.7" spread="226.05"/>
                    <measurement group_id="O2" value="320.4" spread="205.6"/>
                    <measurement group_id="O3" value="224.8" spread="164.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Xibrom</title>
          <description>Xibrom to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
        </group>
        <group group_id="E2">
          <title>Nevanac</title>
          <description>Nevanac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery</description>
        </group>
        <group group_id="E3">
          <title>Acuvail</title>
          <description>Acuvail to be given preoperatively. One drop BID, 1 day pre op and day of surgery 3 doses prior to surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frank A. Bucci, Jr., MD</name_or_title>
      <organization>Bucci Laser Vision</organization>
      <phone>570-825-5949</phone>
      <email>Buccivision@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

